UNSPSC 51111739: Etoposide

This classification denotes an epipodophyllotoxin compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6PLQ3CP4P3. European Medicines Agency schedules Etoposide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07337MIG. Etoposide generally arises in the molecular formula C29H32O13.

UNSPSC 51111739 Etoposide is a Commodity code covering pharmaceutical products, though recent state and local solicitations show minimal activity directly aligned with this specific drug. The code nominally covers etoposide, a chemotherapy agent, but the posted opportunities under this code classification involve other pharmaceutical products—antibiotics, naloxone, and drug deactivation systems—suggesting either misclassification in state and local procurement systems or that etoposide procurement is not currently active in the posted opportunity stream. State and local health departments and county public health agencies are the primary issuing bodies engaging in pharmaceutical procurement, with purchasing typically structured through cooperative vehicles such as MMCAP Infuse and competitive invitation for bid processes.

Recent activity appears limited and geographically dispersed. Illinois Department of Public Health awarded a pharmaceutical piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for antibiotic products valued at $2,999,999.11 over the full contract life (12 months initial plus two optional renewal years), while Seminole County, Florida released an IFB in June 2026 seeking annual supplies of naloxone (1,900 units) and drug deactivation systems (800 units) with quarterly deliveries and a two-year initial term plus one-year renewal option. Neither opportunity directly solicits etoposide; the code shows little recent relevant state and local procurement activity aligned with its nominal scope.